Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 6/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | PRKCG | P05129 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938173 | 0.88 | MAP2K1 (0.52) | NR4A2MAP2K1AXLLRRK2CDK2 | |
| SCHEMBL9937764 | 0.86 | JAK3 (0.57) | JAK3JAK2 | |
| SCHEMBL1839435 | 0.84 | LRRK2 (0.51) | NR4A2MAP2K1AXLLRRK2CDK2 | |
| SCHEMBL30122008 | 0.83 | CSNK2A1 (0.52) | NR4A2MAP2K1AXLLRRK2CDK2 | |
| SCHEMBL17818839 | 0.83 | CSNK2A1 (0.52) | NR4A2MAP2K1AXLLRRK2CDK2 | |
| SCHEMBL30365873 | 0.82 | MAP2K1 (0.56) | NR4A2MAP2K1AXLPKMJAK3 | |
| SCHEMBL22553986 | 0.82 | MAP2K1 (0.56) | NR4A2MAP2K1AXLPKMJAK3 | |
| SCHEMBL24672390 | 0.81 | CDK8 (0.62) | MAP2K1AXLLRRK2CDK2CDK9 | |
| SCHEMBL30668776 | 0.81 | CDK8 (0.62) | MAP2K1AXLLRRK2CDK2CDK9 | |
| SCHEMBL29953241 | 0.79 | MAP2K1 (0.54) | NR4A2MAP2K1AXLPIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
| EP-3233841-A1 | INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | Merck Patent GmbH (DE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100281-A1 | INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100281-A1 | INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | NR4A2 683/4885MAP2K1 2823/4885AXL 1673/4885 |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | NR4A2 789/4885MAP2K1 2647/4885AXL 1868/4885 |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | NR4A2 683/4885MAP2K1 2823/4885AXL 1673/4885 |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | NR4A2 789/4885MAP2K1 2647/4885AXL 1868/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | NR4A2 3760/4885MAP2K1 205/4885AXL 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.